8-K filed Aug 5, 2026 at 07:17 ET
{ "summary": "Lifecore Biomedical reported Q2 2026 revenue of $34.2M (down 6.2% YoY), a GAAP net loss of $6.2M ($0.19 per share vs consensus -$0.17), and Adjusted EBITDA of $8.6M (slightly below $9.1M prior year). Despite the revenue decline and wider net loss, the company reaffirmed its full-year 2026 guidance ($120-125M revenue, $20.5-25M Adjusted EBITDA) and highlighted strong pipeline growth with 13 new programs added over the past 12 months, including 8 late-stage. The combination of stab